Seelos Therapeutics, Inc. Common Stock
SEEL
SEEL was delisted on the 15th of October, 2024.
82 hedge funds and large institutions have $67.8M invested in Seelos Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 30 increasing their positions, 17 reducing their positions, and 19 closing their positions.
1,950% more call options, than puts
Call options by funds: $4.51M | Put options by funds: $220K
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
14% less funds holding
Funds holding: 95 → 82 (-13)
31% less capital invested
Capital invested by funds: $98.2M → $67.8M (-$30.4M)
63% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Group One Trading
Chicago,
Illinois
|
+$1.94M |
| 2 |
GJL
Gendell Jeffrey L
|
+$1.18M |
| 3 |
Two Sigma Investments
New York
|
+$545K |
| 4 |
Morgan Stanley
New York
|
+$415K |
| 5 |
BlackRock
New York
|
+$361K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$1.19M |
| 2 |
Vontobel Holding
Zurich,
Switzerland
|
-$964K |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$722K |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$660K |
| 5 |
Two Sigma Advisers
New York
|
-$599K |
SEEL Hedge Fund Activity: Q4 2021 in Review
82 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q4 2021, worth a combined $67.8M — down 31% from $98.2M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of SEEL and 7 opened new positions — a net loss of 12 holders — while 17 trimmed existing stakes and 30 added.
The largest buyer was Group One Trading, opening a new position worth an estimated $1.94M. The largest seller was Millennium Management, cutting an estimated $1.19M.
- 82 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q4 2021, down from 95 in Q3 2021.
- Funds reported $67.8M of Seelos Therapeutics, Inc. Common Stock stock for Q4 2021, down 31% quarter-over-quarter.
- 7 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q4 2021 and 19 closed out, a net change of -12 holders.
- The largest Seelos Therapeutics, Inc. Common Stock buyer in Q4 2021 was Group One Trading, an estimated $1.94M added.
- The largest Seelos Therapeutics, Inc. Common Stock seller in Q4 2021 was Millennium Management, an estimated $1.19M sold.
Based on aggregated 13F filings for Q4 2021.